Press Releases - WDM Group PR Network  

Cellceutix Acquires PolyMedix Assets From Bankruptcy Court, Gains Ownership of Two Clinical Stage Drugs, Multiple Compounds, and Equipment Assets

Cellceutix Corp.
Leo Ehrlich
(978) 236-8717
Email Contact

Stem Cell Therapeutics Advances CD47 Antagonist Program Into IND-Enabling Phase

Stem Cell Therapeutics Corp.
James Parsons
Chief Financial Officer
+1 416 595 0627
jparsons@stemcellthera.com
www.stemcellthera.com
or
ProActive Capital
Jeff Ramson
Investor Contact
+1 646-863-6519
jramson@proactivecapital.com
or
ProActive Capital
Kirin Smith
Investor Contact
+1 646-863-6519
ksmith@proactivecapital.com

Miraculins Announces Publication of Comprehensive Review Article on Skin Cholesterol and Its Link to Increased Cardiovascular Risk

Miraculins Inc.
Christopher Moreau
President & CEO
204-477-7599
204-453-1546 (FAX)
info@miraculins.com
www.miraculins.com

AXXESS Pharma Inc. Signs Agreement With Top Mexican Pharmaceutical Company

Contact:
Investor Relations
Taylor Capitol, Inc.
Stephen Taylor
(973) 351-3868
STEPHTAYL9@AOL.COM
www.TheStockAlerts.com

PLX Features PCIe-Based Top-of-Rack Demonstration at Intel Developer Forum

SUNNYVALE, CA--(Marketwired - September 9, 2013) - PLX Technology, Inc. (NASDAQ: PLXT), the global leader in PCI Express® (PCIe®) silicon and software connectivity solutions enabling emerging data center architectures, today announced it will showcase at this week's Intel Developer Forum...

Peregrine Pharmaceuticals Reports First Quarter Fiscal Year 2014 Financial Results and Recent Developments

Contact:

Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

Living Beyond Breast Cancer Releases New Publication

Kevin Gianotto
Associate Director, Marketing and Corporate Partnerships

Living Beyond Breast Cancer
354 West Lancaster Avenue
Suite 224
Haverford, PA 19041

Direct: (484) 708-1547

Endexx Provides Contract Clarification and Compliance Requirements

Contact:
Todd Davis
Endexx Corporation
480-595-6900
Todd.Davis@endexx.com

VXI Presentations, Annual Meeting, and VXI Member Booths at AUTOTESTCON 2013

VXIbus Consortium Contact:
Bob Helsel
Email Contact
Executive Director

Data Supporting Bavituximab's Immunotherapy Mechanism of Action Published in the Peer-Reviewed AACR Journal Cancer Immunology Research

Contact:

Christopher Keenan
Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | 32 | 33 | 34 | 35 | 36 | 37 | 38 | 39 | 40 | 41 | 42 | 43 | 44 | 45 | 46 | 47 | 48 | 49 | 50 | 51 | 52 | 53 | 54 | 55 | 56 | 57 | 58 | 59 | 60 | 61 | 62 | 63 | 64 |


Featured Articles + MORE Featured Articles >>